• By ICR Secretariat
  • Posted Thursday, July 14, 2022

NICE recommends Opdivo as post-surgery treatment

https://www.pharmatimes.com/news/nice_recommends_opdivo_as_post-surgery_treatment_1451648

Bristol Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending Opdivo (nivolumab) for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma (MIUC).